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ABSTRACT 
Objective: To investigate the effect of surfactant and specific 
antibody on bacterial proliferation in experimental pneumo- 
coccal pneumonia. 
Methods: Near-term newborn rabbits received a standard dose 
(IO’) of type 3 pneumococci via the airways. Control animals 
were sacrificed 1 minute later. Other animals were ventilated for 
5 hours and treated via the tracheal cannula with surfactant 
(Curosurf 200 mg/kg), a mixture of surfactant and a polyclonal 
antipneumococcal antibody, the antibody without surfactant, 
or saline. 
Results: There was a significant bacterial proliferation in lung tis- 
sue in all animals ventilated for 5 hours. Bacterial growth, 
expressed as log,0 colony forming units (CFU) per gram of lung 
tissue was less prominent in animals treated with a mixture of 
surfactant and specific antibody than in animals treated with 
antibody alone (median, 7.51, range, 6.80-7.70 vs. median, 
7.92, range, 7.07-8.50; P < 0.05). Dynamic lung-thorax com- 
pliance was improved with surfactant or surfactant plus anti- 
body in comparison with saline or antibody alone. 
Conclusion: The data suggest that the suppressive effect of 
the antibody on bacterial proliferation becomes evident only 
when surfactant is administered together with the antibody. 
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Surfactant replacement is an effective treatment not 
only for neonatal respiratory distress syndrome, but also 
for surfactant dysfunction caused by meconium aspi- 
ration or congenital pneumonia.1-J Experimental data 
indicate improved lung function after surfactant ther- 
apy in adult rats with pneumonia caused by Sendai 
virus,* Pneumocystis carinii,5 and Escherichia coli,’ 
and in mice with influenza A viral pneumonia.’ How- 
ever, before this treatment can be recommended in the 
clinical management of bacterial or viral pneumonia, 
possible interactions between different exogenous sur- 
factants and various invading microorganisms should 
be explored. Some systematic studies addressing this 
issue have been performed. In near-term newborn rab- 
bits with experimental pneumonia induced by group B 
streptococci, a reduction in bacterial growth was 
reported after treatment with a synthetic surfactant 
substitute (Exosurf NeonatalTM, Burroughs Wellcome, 
Research Triangle Park, Durham, NC, USA) or modified 
natural surfactant isolated from pig lungs (Curosurp, 
Chiesi Farmaceutici, Parma, Italy).8,” 
Although Streptococcus pneumoniae (pneumococ- 
cus) rarely causes pneumonia in the neonatal period, it 
is an important source of morbidity and mortality in chil- 
dren and elderly persons.‘Oxll In adults, pneumococci are 
a common cause of community-acquired pneumonia, 
which carries a mortality of 5 to 10% despite modern 
antimicrobial therapy and intensive care.‘” In childhood, 
infection with penumococci is a common cause of acute 
otitis media,i3 pneumonia, meningitis, and sinuitis.lo Pneu- 
mococcal infections will become more difficult to man- 
age effectively as bacterial resistance to penicillin and 
other antimicrobial agents is now widespread and rapidly 
increasing all over the world.14 Infection with a multidrug- 
resistant pneumococcal strain is a considerable threat in 
childhood.‘5 Unfortunately, currently available 23-valent 
pneumococcal vaccine does not stimulate adequate anti- 
body responses in children less than 2 years old,i6 debil- 
itated elderly persons,” or individuals with compromised 
immune system. ‘8,19 Passive immunization with specific 
antibodies against capsular polysaccharides represents 
an alternative approach to protection of children at high 
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risk of pneumococcal infection attributable to congeni- 
tal OT acquired immune defects or exposure to secondary 
infection.20-23 
The present article describes a new experimental 
model of pneumococcal pneumonia in near-term new- 
born rabbits. This model was used to investigate whether 
pulmonary function and proliferation of bacteria in lung 
tissue were influenced by treatment with surfactant or 
administration of a specific antibacterial antibody via the 
airways. Another goal was to determine whether the 
effect of the antibody was potentiated by simultaneous 
treatment with surfactant. 
MATERIALS AND METHODS 
sutictaut 
Curosurf is prepared from minced pig lungs by a com- 
bination of washing, centrifugation, chloroform-methanol 
extraction, and liquid-gel chromatography. The isolated 
polar lipid fraction is dissolved in chloroform and steril- 
ized by a high-pressure micropore filter system. Curosurf 
contains 41 to 48% saturated phosphatidylcholine, 51 to 
58% other phospholipids, and about 1% hydrophobic pro- 
teins (SP-B, SP-C). Neutral lipids (including triacylglycerol, 
cholesterol, and cholesterol esters) are removed by the 
chromatography procedure. The final product is sus- 
pended in normal saline at a concentration of 80 mg/mL. 
The physiologic effects of Curosurf on the immature 
neonatal lung, including improvement of gas exchange 
and lung compliance as well as increased survival, have 
been confiied in animal experiments and in randomized 
clinical trials.24 
Bacteria 
An encapsulated pneumococcal type 3 strain (9406) 
previously shown to cause infections in rabbits,25 was 
used for the present experiments. The strain, which was 
stored in aliquots at -70°C was inoculated into 10 mL 
of trypticase soy broth (TSB 3% w/v, Becton Dickinson, 
Cockeysville, MD) on the day before the experiments. 
After an 1 l-hour incubation at 37°C this suspension was 
inoculated into another 200 mL of TSB and cultured for 
3 hours to obtain mid-logarithmic growth phase organ- 
isms. The bacteria were centrifuged at 900 times gravity 
for 10 minutes at 4°C and then washed and resuspended 
in sterile saline. The optical density of the suspension 
was measured spectrophotometrically at 595 nm and 
adjusted to a value corresponding to -10’ colony form- 
ing units (CFU) per milliliter. The exact number of viable 
bacteria was determined by doing a serial dilution of 
the bacterial suspension in sterile saline. Aliquots (100 
PL) from the dilutions lo-’ to lo-” were spread on agar 
plates (5% sheep blood agar) for colony counting and 
incubated for 24 hours at 37°C in air with 5% CO,, to 
promote growth. Each step was carried out in duplicate, 
and the average count from two plates was used for fur- 
ther calculations. 
Production of Polyclonal Antibody 
Type 3 pneumococci (strain 9406) were grown in 3% 
TSB for 18 hours at 37°C. The culture was centrifuged 
and washed twice with phosphate buffered saline (PBS) 
at 2000 times gravity for 15 minutes at 4°C. The pellet 
was resuspended in 10 mL of PBS, and an aliquot was 
used for bacteria counting, as described above. The sus- 
pension was heated to 80°C for 1 hour in a water bath, 
subsequently checked for sterility, and stored at 4°C 
until use. The suspension was diluted with PBS to a 
concentration of 1 X lo* CFU/mL. The polyclonal anti- 
body was raised in adult New Zealand White rabbits 
by repeated intravenous immunization with the heat- 
killed bacteria. The antiserum thus obtained exhibited 
enzyme-linked immunosorbent assay (ELISA) titers rang- 
ing from l/SO to over l/10,240 against the homolo- 
gous strain. The IgG fraction was extracted by high 
performance preparative affinity chromatography on a 
protein A column (Sephadex 6-MB, Pharmacia, Uppsala, 
Sweden). The eluted IgG was concentrated and desalted 
with amnicon filter (Centriplus-100 Millipore AB, Sund- 
byberg, Sweden). 
Animal Experiments 
New Zealand White rabbit fetuses were delivered by 
hysterotomy at a gestational age of 29.5 days. The ani- 
mals were anesthetized with intraperitoneal sodium pen- 
tobarbital (Mebumal Vet, 6 mg/mL, Nordvacc, 
Skarholmen, Sweden; dose 3 mL/kg), tracheotomized, 
and kept in individual boxes in a body plethysmograph 
system, at 37°C. They were relaxed with intraperitoneal 
pancuronium bromide (Pavulon, 0.2 mg/mL, Organon, 
Goteborg, Sweden; dose 3 mL/kg) and connected in par- 
allel to a pressure-controlled Servo 900 B ventilator 
(Siemens-Elema, Solna, Sweden) delivering 100% 0, at a 
working pressure of 60 cm H,O, a frequency of 40 
breaths per minute, and an inspiration:expiration ratio 
of 1:l. Tidal volumes were recorded with a specially 
designed “Fleisch tube” connected to the plethysmo- 
graph box, a differential pressure transducer (EMT 32, 
Siemens-Elema), an integrator unit (EMT 41, Siemens- 
Elema), and an amplifier (EMT 3 1, Siemens-Elema) and 
kept at 8 to 10 mL/kg by adjusting individually the peak 
pressure of the different boxes2” No positive end-expi- 
ratory pressure was applied. The insufflation pressure 
was recorded with a pressure transducer (EMT 34; 
Siemens-Elema), and the dynamic compliance of the res- 
piratory system was calculated by dividing the tidal vol- 
ume per kilogram of body weight by the corresponding 
peak insufflation pressure. Tidal volumes, insufflation 
pressures, and electrocardiogram (ECG) readings were 
recorded on a multichannel recorder (Mingograf 710, 
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Siemens-Elema) every 15 minutes during the first hour, 
and every 30 minutes throughout the rest of the exper- 
iment. Animals with severe ECG abnormalities (heart 
rate <lOO beats/min, arrhythmia, or atrioventricular 
block) were counted as nonsurvivors and excluded from 
the final statistics. 
Protocol I. Injhence of Exogenous 
Surfatant on Bacterial Proliferation 
A total of 30 animals from five litters were allocated at 
random to the following three groups: 
Growth controls. These animals received 5 mL/kg of 
the bacterial suspension instilled via the tracheal cannula 
15 minutes after onset of ventilation, and were then ven- 
tilated for 1 more minute to move the instilled bacteria 
from the central airways to the periphery of the lung. 
The number of CFU in lung cultures from these animals 
served as a baseline for evaluation of bacterial prolifera- 
tion in the other two groups. 
Curosurf group. These animals received the standard 
dose of bacterial suspension (5 mL/kg) at 15 minutes. 
After another 15 minutes, 2.5 mL/kg of Curosurf (200 
mg/kg) was administered by intratracheal bolus injection. 
The animals were then ventilated for another 4.5 hours 
(total, 5 hours). This period of ventilation was chosen on 
the basis of data from previous similar studies on group 
B streptococcal pneumonia in newborn rabbits. During 
this time period, significant proliferation of bacteria could 
be demonstrated in infected animals not receiving sur- 
factant or antibacterial antibody, and this was associated 
with prominent recruitment of granulocytes to the air 
spaces.’ 
Saline group. After tracheal instillation of the bacte- 
rial suspension (5 mL/kg) at 15 minutes, these animals 
received 2.5 mL/kg of sterile saline at 30 minutes. They 
were then ventilated for a total of 5 hours. 
After the scheduled period of ventilation, the animals 
were sacrificed by intracerebral injection of 0.5 mL lido- 
Caine (Xylocaine 20 mg/mL, Astra, Soderdlje, Sweden). 
The abdomen was opened with sterile instruments, and 
the diaphragm was inspected for evidence of pneu- 
mothorax. The thorax was opened by a midline incision 
through the sternum, and blood was sampled from the 
right ventricle for bacterial culture (Sigma Oxoid Blood 
Culture System, Unipath, Basingstoke, UK). 
Processing of Lungs. Both lungs were removed asepti- 
cally. The left lung was used for quantification of bacter- 
ial growth. The lung was weighed, processed in a tissue 
homogenizer (Sorvall Ominimix, DuPont Instruments, 
Newtown, CT), and serially diluted. The number of CFU 
was determined on coded samples as described above. 
The number of CFU per gram of lung tissue (wet weight) 
was used to indicate the amount of viable bacteria. 
The right lung was fured by immersion in 4% neutral 
formalin and embedded in paraffin. Longitudinal sections 
were cut from the middle of each paraffin block in a 
standardized fashion. The sections were stained with 
hematoxylin and eosin or with Gram stain and examined 
under a light microscope, with particular reference to 
evidence of pneumonia as indicated by intra-alveolar 
accumulation of leukocytes. The proportion of pulmonary 
parenchyma with pneumonia was estimated using a four- 
grade scale: 0, less than lo%, 10 to 30%, and more than 
30%.’ An arbitrary four-grade scoring system (absent, mild, 
moderate, severe) was used for estimating the degree of 
intra-alveolar edema, necrosis of airway epithelium, intra- 
alveolar and interstitial hemorrhage, and hyaline mem- 
branes. Since bacterial growth was assessed more 
precisely by microbiologic methods, no effort was made 
to quantify the number of bacteria in the Gram-stained 
sections. The histologic examination was performed on 
coded material, (i.e., without knowledge of the experi- 
mental conditions of individual animals). 
Protocol II. Injluence of Specific 
Antibody on Bactertal Proliferation 
A total of 50 animals from eight litters were used for 
these experiments. They were allocated at random to the 
following four groups, all receiving the standard dose of 
bacterial suspension (5 mL/kg) at 15 minutes: 
Growth controls. The experimental conditions were 
the same as in the corresponding group in Protocol I. 
Antibody group. These animals received 5 mL/kg of 
the antibody solution (2.5 mg/mL) via the tracheal can- 
nula at 30 minutes and were ventilated for a total of 5 
hours. 
Curosurf + antibody group. A mixture of Curosurf 
and antibody solution was instilled into the airways at 
30 minutes at a dose volume of 5 mL/kg. The concen- 
trations of Curosurf and antibody in the mixture were 
40 mg/mL and 2.5 mg/mL, respectively Total time of ven- 
tilation was 5 hours. 
Saline group. These animals received 5 mL/kg of 
saline at 30 minutes. Total time of ventilation was 5 hours. 
Processing and Examination of Lungs. The left lung 
was removed aseptically after ligation of the main 
bronchus. The lung was divided into two pieces with a 
sagittal section, and these specimens were weighed. The 
lateral portion of the left lung was kept in a test tube on 
ice for subsequent quantification of bacterial growth in 
homogenized tissue as described above. The remaining 
piece of the left lung was fixed in 4% neutral formalin and 
further processed for histologic examination according to 
the same principles as in Protocol I. The right lung was 
lavaged in situ with normal saline containing 2 U of 
heparin per milliliter. A volume corresponding to 20 
12 International Journal of Infectious Diseases / Volume 5, Number 1 
mL/kg was instilled and withdrawn three times via the tra- 
cheal cannula, and this procedure was repeated five times, 
with a total recovery of 88 + 8.9% (mean + SD). 
Table 2. Number of Pneumococci Instilled Into the Airways and 
Lung Content of Pneumococci in Different Treatment Groups 
Treatment CFU Instilled* CFU/g Lung Tissue* 
Cell Counting. The lavage fluid was centrifuged at 150 
times gravity for 10 minutes, and the resulting pellet was 
resuspended in 1 mL of normal saline. Then 100 PL of 
this suspension was stained with Giemsa-Romanowski 
stain and the cells were counted in a Biirker chamber. 
Conventional cytospin preparations from the rest of the 
suspension were stained with May-Griinwald-Giemsa stain 
for microscopic differential counting of inflammatory 
cells. A total of 200 cells were counted in each animal. 
Protocol I 
Curosurf (n = 10) 7.48 (6.78-7.76) a.01 (7.58-8.70)+ 
Saline (n = 10) 7.47 (6.78-7.68) a.1 1 (7.56-8.95)+ 
Growth controls 
(n = 9) 7.56 (6.70-7.71) 6.58 (6.03-6.95) 
Protocol II 
Antibody (n = 11) 7.06 (6.50-7.71) 7.92 (7.07-a.50)+ 
Curosurf + antibody 
(n = 9) 7.12 (6.50-7.78) 7.51 (6.80-7.70)+~ 
Saline (n = 9) 7.29 (6.50-7.69) 7.86 (6.20-8.21)+ 
Growth controls 
(n= 11) 7.43 (6.50-7.69) 6.90 (5.56-7.28) 
Ethical Approval 
The animal experiments observed the Swedish animal 
protection law and were approved by the local commit- 
tee for animal research. 
Statistics 
Values are given as means 5 SD or as median (range) when 
not normally distributed. All figures for bacterial prolifera- 
tion were transformed into decimal logarithms (log& Dif- 
ferences between groups were evaluated by analysis of 
variance (ANOVA) followed by the Student-Newman-Keuls 
test, or Kruskal-Wallis test (for data on bacterial prolifera- 
tion in lung tissue, and cell counts of lung lavage fluid) fol- 
lowed by Mann-Whitney test with Bonferroni corrections. 
Chi-squared test and Fisher’s exact test were applied for 
evaluation of histologic data and blood culture results. The 
CRISP statistical program (Crunch Software, San Francisco, 
CA) was used for these calculations, and P-values less than 
0.05 were considered statistically significant. 
RESULTS 
General Observations in Animal Experiments 
Survival rate, body weight, and final heart rate in animals 
surviving the scheduled 5-hour period of ventilation are 
Table 1. Characterization of Animals in Different Treatment Groups 
Final Heart 
Rate in 
Survival Rate Body Weight* Survivors * 
Treatment Group (W (9) (beats/min) 
Protocol I 
Curosurf 1 O/l 0 (100) 38 + a 231 t 20 
Saline IO/l1 (91) 39 -t 5 249 t 28 
Growth controls 49 39 t 5 224 t 64 
Protocol II 
Antibody 1 l/12 (92) 39 2 a 237 t 46 
Curosurf + antibody 9/l 2 (75) 42211 265 t 40 
Saline 9/l 5 (60) 40 t 7 243 -f 59 
Growth controls -I1 1 34 t 6 240 k 83 
*Mean ? SD 
*Values are expressed as log,o colony forming units (CFU) and given as median 
and range: +P < 0.001 vs. growth controls; *P < 0.05 vs. each of antibody and 
saline groups. 
Kruskal-Wallis test for nonrandom distribution of data: P < 0.001 for both 
Protocol I and Protocol II, 
shown in Table 1. There were no statistically significant 
differences in these parameters between the groups. 
Protocol I 
Bacterial Proliferation 
The calculated log,, number of bacteria given into the 
airways was similar in the growth control, Curosurf, and 
saline groups (Table 2). The number of CFU in left lung 
homogenate from the growth control animals was lower 
than the number of CFU in the volume of instilled bac- 
terial suspension. However, there was a significant pro- 
liferation of bacteria in animals ventilated for 5 hours 
after treatment with Curosurf or saline, without a sta- 
tistically significant difference between these groups (see 
Table 2). Blood cultures were positive for pneumococci 
in one of the nine growth control animals, in six of ten 
infected animals treated with Curosurf (P < 0.05 vs. 
growth controls), and in nine of ten infected animals 
treated with saline (P < 0.001 vs. growth controls). The 
difference between these two latter groups was not sta- 
tistically significant. 
Lung-Thorax Compliance 
Mean values for lung-thorax compliance at 15 minutes 
indicated lung maturity in these near-term animals, 
although with considerable individual variation (Table 3).26 
The slight decrease in compliance noted after intra- 
tracheal instillation of 5 mL/kg of fluid at 15 minutes was 
not statistically significant. After treatment at 30 minutes, 
compliance was significantly higher in animals that 
received Curosurf than in those that received saline, and 
remained so during the rest of the experiment (P < 
0.05-0.01). In both groups there was a gradual decrease 
in compliance during the period of observation. 
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Table 3. Lung-Thorax Compliance in Infected 
Animals Ventilated for 5 Hours (Protocol I) 
Compliance (mUcm H,O.kg)/Treatment* 
Time (min) Curosurf (n = 10) Saline (n = 70) 
15+ 
30* 
45 
60 
90 
120 
150 
180 
210 
240 
270 
300 
0.79 z 0.18 0.62 t 0.40 
0.65 2 0.21 0.50 t 0.15 
0.66 2 0.09 0.47 + 0.114 
0.66 k 0.09 0.46 i- 0.115 
0.61 2 0.06 0.45 + 0.095 
0.59 k 0.05 0.47 + 0.12” 
0.58 + 0.04 0.45 -c 0.09” 
0.57 + 0.08 0.43 t- 0.105 
0.58 + 0.06 0.45 2 0.16” 
0.61 k 0.16 0.42 2 0.161 
0.56 2 0.08 0.41 i 0.161 
0.56 -c 0.10 0.37 ? 0.145 
*Values are given as mean ? SD: ibefore instillation of pneumococci; ibefore 
instillation of Curosurf or saline; §P < 0.01 between the groups: nP < 0.05 
between the groups. 
Histologic Evaluation 
An inflammatory reaction, characterized by accumulation 
of granulocytes in the air spaces, was found in 19 of the 
20 infected animals ventilated for 5 hours. This reaction 
was graded as mild-to-moderate in most animals, without 
differences between the two groups. In one of the ani- 
mals allocated to the saline group, the inflammatory reac- 
tion was graded as severe. One of the nine growth control 
animals had mild inflammatory reaction (grade 1); the 
remaining eight animals in this group showed no accu- 
mulation of granulocytes in the air spaces (P < 0.01 vs. 
Curosurf and saline groups). Hyaline membranes, absent 
in the growth control animals, were present in two of 
the Curosurf-treated (NS) and in five of the saline-treated 
animals (P < 0.05 vs. growth controls) (Figure 1,A). The 
degree of membrane formation in affected animals ranged 
from mild to severe in both groups. Mild focal necrosis 
of airway epithelium was found in five of the growth 
control animals. Airway epithelial necrosis was rated as 
mild-to-moderate in nine Curosurf-treated, and as mild-to- 
prominent in nine saline-treated animals (P < 0.05 and 
0.01, respectively, vs. growth controls). 
Protocol II 
Bacterial Proliferat#on 
The various groups of infected animals received nearly 
the same dose of pneumococci (see Table 2). After 
5 hours of ventilation, there was a statistically significant 
Figure 1. Histologic findings in lung tissue from infected animals ven- 
tilated for 5 hours. A, Area of alveolar collapse with thick hyaline mem- 
branes but only few inflammatory cells in the air spaces in saline-treated 
animal (Protocol I). 6, Prominent intra-alveolar accumulation of gran- 
ulocytes in saline-treated animal (Protocol II). C, Less prominent, but 
otherwise similar, inflammatory reaction in animal receiving Curosurf + 
antibody (Protocol II). (H&E, original magnification xl 40). 
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Figure 2. Dynamic lung-thorax compliance in the three treatment 
groups during 5 hours of ventilation (Protocol II): antibody group, 
-X--; curosurf + antibody group, -A-; saline group, -n--. 
From 60 minutes to 300 minutes, the differences between the Curo- 
surf + antibody group and each of the other two groups are sta- 
tistically significant (P < 0.01). 
proliferation of bacteria in the three treatment groups in 
comparison with growth controls (Kruskal-Wallis test for 
nonrandom distribution of data, P < O.OOl), but this pro- 
liferation was less prominent in the Curosurf + antibody 
group than in animals receiving only antibody or saline 
alone (P < 0.05) (see Table 2). Blood cultures were pos- 
itive for pneumococci in one of the eleven growth con- 
trols, in ten of the eleven animals in the antibody group, 
in six of the nine animals in the Curosurf + antibody 
group, and in all nine animals in the saline group 
(P < 0.001,0.05, and 0.001, respectively, vs. growth con- 
trols). There were no statistically significant differences 
between the groups ventilated for 5 hours. 
Lung-Thorax Compliance 
As illustrated in Figure 2, initial values for lung-thorax 
compliance were nearly the same in the three groups of 
animals subjected to prolonged ventilation. After instilla- 
tion of the bacterial suspension at 15 minutes, there was 
a slight reduction in compliance, similar in all three 
groups. However, from 60 minutes and onward compli- 
ance was higher in the Curosurf + antibody group than 
in each of the other two treatment groups. This difference 
was statistically significant at all subsequent time points 
(P < 0.01). Final values for compliance, recorded at 
5 hours, were 0.62 ? 0.06 in the Curosurf + antibody 
group, 0.32 + 0.15 in the antibody group, and 0.42 +- 
0.19 in the saline group. 
Histologic Evaluation 
An inflammatory reaction with recruitment of granulo- 
cytes to the air spaces was present in all infected ani- 
mals ventilated for 5 hours (see Figure 1, B and C). No 
such changes were found in the growth controls 
(P < 0.001). Inflammatory changes graded as severe were 
found in seven animals in the antibody group, two animals 
in the Curosurf + antibody group, and six animals in the 
saline group (no statistically significant differences 
between the groups). Hyaline membranes were absent 
in all growth control animals, but present in eight of the 
antibody-treated animals (P < 0.001 vs. growth controls), 
in four of the animals receiving Curosurf + antibody (P 
< 0.05) and in eight of the animals treated with saline (P 
< 0.001). In general, the injury score indicated less promi- 
nent hyaline membranes in the Curosurf + antibody 
group than in each of the other two treatment groups, 
but these differences were not statistically significant (P 
> 0.06). Airway epithelial necrosis, graded as mild-to- 
severe, was present in all animals in the antibody and 
saline groups, and in all but two animals in the Curosurf 
+ antibody group. Mild focal airway epithelial necrosis 
was observed in one of the growth controls; in the 
remaining 10 animals in this group the bronchial epithe- 
lium was intact (P < 0.001 vs. antibody and saline groups, 
and P < 0.05 vs. Curosurf + antibody group). Epithelial 
necrosis was graded as severe in eight animals in the anti- 
body group, in none of the animals in the Curosurf + 
antibody group, and in four animals in the saline group 
(antibody vs. Curosurf + antibody group: P < 0.05). 
Cell Counts 
Total number of cells in the lavage fluid and the pro- 
portion of granulocytes determined from cytospin prepa- 
rations were increased in each of the three groups of 
animals ventilated for 5 hours (P < 0.01 vs. growth con- 
trols), however, without statistically sign&ant differences 
between these groups (Table 4). 
Statistical Evaluation of Combined 
Data from Protocols I and II 
In addition to the statistical analysis given above, data 
obtained with the two protocols were analyzed together. 
Combined data from the two growth control groups were 
used to draw a regression line showing the correlation 
between the total dose of bacteria (CFU) given to each 
of these neonates and the number of CFU cultured in 
lung tissue from the same animals. Using this regression 
line (y = 0.66 x + 1.78; r = 0.61; P < 0.004) the baseline 
(l-mm) value for number of CFU in lung tissue could be 
estimated for animals ventilated for 5 hours after receiv- 
Table 4. Cell Counts of Lung Lavage Fluid 
in Different Treatment Groups (Protocol II) 
Total Cells/Animal (X 104, Granulocytes (%) 
Treatment Group Median (Range) Median (Range) 
Antibody 313 (16%2393)* 14.5 (O-95.5)* 
Curosurf + antibody 464 (13s2590)* 11.5 (O-81.5)$ 
Saline 559 (1 l-l 558)+ 14.5 (O-94.0)f 
Growth controls 53 (1 I-107) 0 (O-4.5) 
*P i 0,001; +P < 0.05; *P < 0.01 vs. growth controls. 
Figure 3. Proliferation of pneumococci in lung tissue combined-treat- 
ment groups (Protocols I + II). Values for bacterial proliferation were 
calculated by subtracting the estimated initial lung content of bacteria 
from the lung content of bacteria determined after 5 hours. Bars rep- 
resent median and range, Bacterial proliferation is clearly reduced in 
animals treated with Curosurf + antibody (Kruskal-Wallis test for non- 
random distribution of data: P < 0.053; P < 0.05 vs. each of the saline 
and Curosurf groups). 
ing slightly different doses of bacteria. For each animal, 
the proliferation of bacteria during the entire period of 
observation was then calculated by subtracting the esti- 
mated value for CFU in lung tissue at 1 minute from that 
found by bacterial culture after 5 hours. In the final analy- 
sis, the saline control groups from the two protocols also 
were combined. The data generated by these calculations 
demonstrate that bacterial proliferation was nearly the 
same in the saline, Curosurf, and antibody groups, but 
clearly reduced in animals treated with Curosurf plus 
antibody (Kruskal-Wallis test for nonrandom distribution 
of data: P < 0.053; P < 0.05 vs. saline group; P < 0.05 vs. 
Curosurf group) (Figure 3). 
DISCUSSION 
More than 80 serotypes of S.pneumoniae have been 
identified on the basis of antigenic differences in their 
capsular polysaccharides. In the present experiments, 
type 3 pneumococcus was selected because it has the 
largest capsule and is among the most invasive of all 
pneumococcal subtypes.27 It has a recognized ability to 
produce severe pneumonia and septicemia in high-risk 
groups, including patients with preceding viral respira- 
tory tract infection, immunodeficiency syndromes, splenic 
dysfunction or splenectomy, chronic obstructive pul- 
monary disease, treatment with anesthetic agents, and 
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alcoholism.28~29 The mortality of patients infected with 
type 3 pneumococcus is for pneumonia 5% and for sep- 
ticemia 2O%.‘O Infections with this particular micro- 
organism thus represent an important clinical problem, 
and some patients with respiratory failure attributable to 
pneumococcal infection may, in the future, be considered 
candidates for surfactant replacement therapy. 
The rate of clearance of inhaled pneumococci 
depends on a variety of factors, including bacterial sub- 
type, dose of bacteria, and immunocompetence of the 
host. Furthermore, the mechanism for killing inhaled 
pneumococci varies among species.3’ A direct compari- 
son of the present results with data published in the lit- 
erature is not possible, because different pneumococcal 
subtypes and host species were used, and different modes 
of infection and doses of bacteria were applied in the 
studies published by other investigators. For example, it 
has been reported that inhaled pneumococci are rapidly 
killed in guinea pigss2 In contrast, the present results 
indicated proliferation of pneumococci during a 5-hour 
period of mechanical ventilation. In these experiments 
the animals were paralyzed, tracheotomized and kept in 
a supine position, which might have enhanced bacterial 
growth in comparison with animals breathing sponta- 
neously in an aerosolization chamber, as was the case in 
the experiments on guinea pigs.“2 On the other hand, 
the experimental design of the present study simulated 
the condition of critically ill, immobilized, and ventilated 
patients with pneumococcal pneumonia. 
The authors chose to perform the experiments on 
ventilated newborn rabbits, having had considerable expe- 
rience with the use of surfactant in this model for treat- 
ment of inflammatory lung diseases, such as meconium 
aspiration syndrome and group B streptococcal pneu- 
monia.“~s3,‘4 Pneumococcal pneumonia is a rare disease in 
the neonatal period and the influx of macrophages into 
the air spaces normally does not surge until later after 
birth.“5,3” However, in the present experiments, lungs of 
infected animals showed significant recruitment of gran- 
ulocytes to the bronchiolar and alveolar compartments, 
similar to the nonspecific inflammatory reaction seen in 
lobar pneumonia caused by infection with pneumococci. 
It is reassuring that treatment with Curosurf did not 
promote proliferation of pneumococci in comparison 
with infected animals receiving saline. Herting and col- 
leagues found that Curosurf reduced proliferation of 
group B streptococci in newborn rabbits ventilated with 
the same method,” and other authors have reported, from 
studies on rats and rabbits, that natural surfactant may 
enhance phagocytosis and intracellular killing of Staphy- 
Zococcus aureus by alveolar macrophages both in vitro 
and in viva.“‘-j” In contrast, Speer and coworkers found 
slightly reduced bactericidal activity against S. aweus in 
in vitro studies on monocytes exposed to Curosurf or 
surfactant phospholipids alone.*” Similarly, Sherman and 
colleagues reported that treatment of newborn rabbits 
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with natural OT artificial surfactant impaired the capacity 
of lung macrophages to kill inhaled group B strepto- 
cocci.41 Taken together, these data indicate that the mode 
of interaction between exogenous surfactant, inflamma- 
tory cells, and bacteria varies depending on the compo- 
sition of the surfactant,s especially on its content of the 
hydrophilic proteins SP-A and SP-D. (These proteins are 
present in surfactant isolated from lung lavage or amni- 
otic fluid by sucrose density gradient centrifugation but 
absent in surfactant prepared by extraction with organic 
solvents.)** The mode of interaction also varies with the 
type of microorganism involved. Systematic studies con- 
fronting various surfactant preparations with different 
microorganisms under well-standardized experimental 
conditions are required to clarify these various patterns 
of microbiologic interactions. 
Lung-thorax compliance of infected animals treated 
with antibody or saline gradually decreased during the 
course of the experiment, whereas compliance remained 
high in animals treated with Curosurf plus antibody. The 
exogenous surfactant probably counterbalanced the nox- 
ious effects of surfactant inhibitors, especially plasma pro 
teins entering the air spaces with the inflammatory 
exudate. Improved lung function after surfactant treat- 
ment has been observed in various animal models of bac- 
terial and viral pneumonia, and also in newborn babies 
with group B streptococcal pneumonia.1~4~6=7,34~43 Exoge- 
nous lmmunoglobulin apparently does not interfere with 
surfactant function, not even at doses significantly larger 
than those applied in the present study.44-46 
Host defense against pneumococcal infection largely 
depends on opsonization with type-specific antibodies 
and complement, and phagocytosis and killing by poly- 
morphonuclear leukocytes and macrophages.*’ The pneu- 
mococcal capsule is a strong shelter preventing 
phagocytosis of the nonopsonized bacterium2? antibody- 
mediated binding to the Fc receptor of the phagocyte is, 
therefore, a prerequisite for efficient internalization and 
subsequent killing of the microorganism.*’ Although the 
proliferation of pneumococci was clearly inhibited in the 
present experiments by combined treatment with anti- 
body and surfactant, the changes in total lung content of 
bacteria may seem modest. However, the observation time 
was limited to only 5 hours, and the treatment was not 
repeated. To achieve a measurable proliferation during 
the comparatively short period of observation the bac- 
terial load had to be high and was, therefore, difficult to 
neutralize with antibody. Nevertheless, the decrease in 
lung proliferation of bacteria is a realistic measurement 
of treatment efficacy under the present experimental con- 
ditions. Bactericidal antibiotics are probably more effi- 
cient than treatment with specific antibody, but the latter 
approach has the advantage that the bacteria are 
degraded intracellularly (in phagolysomes) rather than in 
the extracellular alveolar compartment. Intracellular pro- 
cessing reduces the risk of epithelial damage caused by 
pneumolysin, a cytotoxic protein,“’ and other products 
released from pneumococci especially when undergoing 
bacteriolysis. 
Findings of this study suggest that surfactant might 
have served as a “carrier,” facilitating dispersion of anti- 
body in the lung. The distribution of the exogenous 
material was not analyzed directly in the present exper- 
iments, but other studies have shown that immunoglob- 
ulin administered by endotracheal instillation is largely 
deposited in the central airways.49 This may explain the 
poor effect of antibody alone in the present experiments, 
especially as the location of infected areas is mostly 
peripheral. Kharasch and colleagues reported that endo- 
tracheally administered pentamidine mixed with surfac- 
tant is distributed more uniformly and reaches more 
peripheral areas in the lung than the same drug mixed 
with normal saline.5o It has also recently been shown that 
treatment with a mixture of surfactant and amoxicillin is 
effective against infection with S. pneumoniae in mice 
and that combined treatment with Curosurf and specific 
immunoglobulin prevents bacterial proliferation in exper- 
imental neonatal group B streptococcal pneumonia more 
effectively than treatment with surfactant a10ne.51z52 All 
these observations suggest that it might be possible to use 
surfactant as a vehicle to improve the intrapulmonary 
dispersion of different therapeutic agents administered 
via the airways5” The authors speculate that surfactant- 
borne specific antibodies might, after additional testing 
in experimental models, find a role in clinical practice 
for treatment of pneumococcal pneumonia, especially 
when caused by bacteria that are multiresistant to anti- 
biotics and with the additional purpose of reducing lung 
injury mediated by release of pneumolysin. 
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